看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
0 k. L4 |8 @% |; b5 ^
7 d8 E' p% {( G4 l: ~$ Y/ X9 p4 _: f6 X) `
Currently available feasibility data for possible combination strategies.
" Q* u" D! p1 u' r% z4 p————————————————————————————————6 S" u" n1 W" r9 B
Combination Feasibility according to preliminary data 9 Z5 C2 ?3 b- j+ U+ W! p4 S4 B
——————————————————————————————————3 V& ? u @, D: f/ f( \, Y
Bevacizumab + sorafenib Yes, reduced dose + q. b# k! e7 ~
Bevacizumab + sunitinib† No / A! O9 a" f: b6 @/ [
Bevacizumab + temsirolimus Yes
% Q# ?: g. T( `2 MBevacizumab + everolimus Yes
8 a8 d3 \+ V8 s! bSorafenib + sunitinib ? ! k% ?5 g; z5 i4 Y+ J* w! m
Sorafenib + temsirolimus Yes, reduced dose
) P7 D6 P/ e) V' }( O7 y USorafenib + everolimus Yes, reduced dose
0 J5 I; y; f+ [, k& CSunitinib + temsirolimus† No {1 q( m5 s- I$ Q6 v! v, }8 f7 @& ~
Sunitinib + everolimus ?
) S/ Y$ D! B8 B1 d' c* Z/ s. S6 [Temsirolimus + everolimus ? 5 ?/ `2 m2 u/ V& J) k
————————————————————, [) d q. ^+ l: ]5 c8 ^/ L* o x
†Led to US FDA warning.
$ e _, h1 O r5 E?: As yet unattempted combination.
6 q% K/ a, l1 F* Y |